Journal article

Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis

Silvia Pineda, Roger L Milne, M Luz Calle, Nathaniel Rothman, Evangelina Lopez de Maturana, Jesus Herranz, Manolis Kogevinas, Stephen J Chanock, Adonina Tardon, Mirari Marquez, Lin T Guey, Montserrat Garcia-Closas, Josep Lloreta, Erin Baum, Anna Gonzalez-Neira, Alfredo Carrato, Arcadi Navarro, Debra T Silverman, Francisco X Real, Nuria Malats

PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2014

Abstract

INTRODUCTION: Germline variants in TP63 have been consistently associated with several tumors, including bladder cancer, indicating the importance of TP53 pathway in cancer genetic susceptibility. However, variants in other related genes, including TP53 rs1042522 (Arg72Pro), still present controversial results. We carried out an in depth assessment of associations between common germline variants in the TP53 pathway and bladder cancer risk. MATERIAL AND METHODS: We investigated 184 tagSNPs from 18 genes in 1,058 cases and 1,138 controls from the Spanish Bladder Cancer/EPICURO Study. Cases were newly-diagnosed bladder cancer patients during 1998-2001. Hospital controls were age-gender, and ar..

View full abstract

Grants

Awarded by Fondo de Investigacion Sanitaria, Spain


Awarded by Red Tematica de Investigacion Cooperativa en Cancer, Spain


Awarded by Marato TV3


Awarded by European Commission


Awarded by US National Institutes of Health


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This work was supported by the Fondo de Investigacion Sanitaria, Spain (grant numbers 00/0745, PI051436, PI061614, G03/174); Red Tematica de Investigacion Cooperativa en Cancer (grant number RD06/0020-RTICC), Spain; Marato TV3 (grant number 050830); European Commission (grant numbers EU-FP7-HEALTH-F2-2008-201663-UROMOL; US National Institutes of Health (grant number USA-NIH-RO1-CA089715); and the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute at the National Institutes of Health, USA; Consolider ONCOBIO (Ministerio de Economia y Competitividad, Madrid, Spain). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.